Table 2.
Studies with at least one enrollment (N=105 total enrollments)
| # | Clinicaltrials.gov or Other Identifier | Brief description | Therapeutic | Intervention Arm Participants Pre-Screened | Intervention Arm Participants Enrolled | % enrolled |
|---|---|---|---|---|---|---|
| 20 | NCT00933595 | Lung infections and complications | 99 | 38 | 38.4% | |
| 1 | PHS 398/2590 | Pneumocystis antigen | 88 | 27 | 30.7% | |
| 9 | NYU LTNP | Long-term non-progressor for treatment naives | 121 | 24 | 19.8% | |
| 10 | NCT00959413 | Oral mucosal disease | 32 | 9 | 28.1% | |
| 24 | NCT00130286 | HIV-associated increased abdominal fat | • | 60 | 2 | 3.3% |
| 2 | NCT00665561 | POEM: Maraviroc safety | 179 | 2 | 1.1% | |
| 3 | NCT00827112 | Novel treatment for treatment naives | • | 17 | 1 | 0.06% |
| 26 | NCT00547S9S | ADVENT: Crofelemer for diarrhea | • | 47 | 1 | 0.02% |
| 4 | NCT00707733 | Phase 3 EVG/r vs RAL | • | 110 | 1 | 0.01% |